Clinical trial
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in Comparison With the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Subjects Eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA) in China
NCT03466151 is registered in ClinicalTrials.gov with Medtronic Vascular as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in Comparison With the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Subjects Eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA) in China
- Lead sponsor
- Medtronic Vascular
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- April 12, 2018
- Completion date
- July 31, 2026
- Enrollment
- 550 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
arteriosclerosis, cardiovascular diseases, coronary artery disease, ischemic heart disease, stenotic coronary lesion